Monitoring for adverse effects from systemic drugs used in dermatology
Identifieur interne : 002E64 ( Main/Exploration ); précédent : 002E63; suivant : 002E65Monitoring for adverse effects from systemic drugs used in dermatology
Auteurs : Stephen E. Wolverton [États-Unis]Source :
- Journal of the American Academy of Dermatology [ 0190-9622 ] ; 1992.
English descriptors
- Teeft :
- Abdominal pain, Abnormality, Acad, Acad dermatol, Adverse effect, Adverse effects, Agranulocytosis, American academy, Antimalarial, Antimalarial therapy, Arch intern, Arthritis, Avascular, Avascular necrosis, Axis function, Axis suppression, Azathioprine, Baseline, Baseline value, Biopsy, Blood urea nitrogen, Bone abnormalities, Bone toxicity, Carcinoma, Cataract, Cessation, Clin, Clinical evaluation, Clinical presentation, Closure, Complication, Coronary artery disease, Corticosteroid, Corticosteroid dose, Corticosteroid therapy, Creatinine, Creatinine clearance, Critical toxicities, Cumulative dose, Cutaneous, Cutaneous conditions, Cyc1osporine, Cyclophosphamide, Cyclosporine, Daily dose, Dapsone, Dapsone therapy, Dermatol, Dermatologic, Dermatology, Determinant, Dos, Early symptoms, Engl, Epiphyseal, Epiphyseal closure, Etretinate, Etretinate therapy, Fasting, Function tests, Growth curve, Growth suppression, Guideline, Hepatocellular, Hepatocellular toxicity, Hepatotoxicity, High doses, High risk, Hyperlipidemia, Hypertension, Immunosuppressive, Immunosuppressive therapy, Inherent risk, Isotretinoin, Isotretinoin therapy, Ketoconazole, Laboratory tests, Lipid, Liver biopsy, Liver function tests, Major drugs, Malignancy, Malignancy induction, Malignancy risk, Methotrexate, Methotrexate therapy, Monitoring, Monitoring process, Ocular, Older patients, Organ transplantation, Osteoporosis, Particular emphasis, Patient characteristics, Photochemotherapy, Physical examination, Platelet, Platelet count, Pneumonitis, Premature epiphyseal closure, Proper monitoring, Psoriasis, Psoriasis patients, Puva, Puva therapy, Renal, Renal function, Renal function tests, Renal toxicity, Reticulocyte count, Retinoid, Retinoid therapy, Retinoids, Retinopathy, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Risk factors, Saunders, Side effects, Skin diseases, Specific toxicity, Syndrome, Systemic, Systemic drugs, Teratogenicity, Testing guidelines, Therapy, Toxicity, Transaminase, Transaminase values, Transplantation, Triglyceride, Uric acid, Urinalysis, Wilkin, Wolverton.
Abstract
Systemic drugs with an associated element of risk are essential in managing many important dermatoses. This review identifies eight major drugs or drug groups used in dermatology that require systematic monitoring for adverse effects. The complete monitoring process is emphasized, including significant patient involvement in reporting key signs or symptoms that allow early diagnosis of many of these adverse effects. The concepts of “risk-risk” assessment and “critical toxicities” are defined, emphasizing their important role in maximizing drug benefits and safety. Drug-related risk factors, disease-specific risk factors, and patient characteristics or habits that increase the risks from systemic drugs are identified. Basic principles of monitoring for adverse effects, specific clinical features of the most important adverse effects, along with detailed monitoring guidelines for methotrexate, retinoids, dapsone, corticosteroids, and cyclosporine are presented.
Url:
DOI: 10.1016/0190-9622(92)70092-T
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000255
- to stream Istex, to step Curation: 000255
- to stream Istex, to step Checkpoint: 001C37
- to stream Main, to step Merge: 002F30
- to stream Main, to step Curation: 002E64
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Monitoring for adverse effects from systemic drugs used in dermatology</title><author><name sortKey="Wolverton, Stephen E" sort="Wolverton, Stephen E" uniqKey="Wolverton S" first="Stephen E." last="Wolverton">Stephen E. Wolverton</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EAAFCF9227565D97E8A3C04430934D14D9AEDC0D</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1016/0190-9622(92)70092-T</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-TLPW2BFC-X/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000255</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000255</idno><idno type="wicri:Area/Istex/Curation">000255</idno><idno type="wicri:Area/Istex/Checkpoint">001C37</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001C37</idno><idno type="wicri:doubleKey">0190-9622:1992:Wolverton S:monitoring:for:adverse</idno><idno type="wicri:Area/Main/Merge">002F30</idno><idno type="wicri:Area/Main/Curation">002E64</idno><idno type="wicri:Area/Main/Exploration">002E64</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Monitoring for adverse effects from systemic drugs used in dermatology</title><author><name sortKey="Wolverton, Stephen E" sort="Wolverton, Stephen E" uniqKey="Wolverton S" first="Stephen E." last="Wolverton">Stephen E. Wolverton</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Indiana</region></placeName><wicri:cityArea>From the Department of Dermatology, Indiana University School of Medicine, Indianapolis</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of the American Academy of Dermatology</title><title level="j" type="abbrev">YMJD</title><idno type="ISSN">0190-9622</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992">1992</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="supplement">P1</biblScope><biblScope unit="page" from="661">661</biblScope><biblScope unit="page" to="679">679</biblScope></imprint><idno type="ISSN">0190-9622</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0190-9622</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abdominal pain</term><term>Abnormality</term><term>Acad</term><term>Acad dermatol</term><term>Adverse effect</term><term>Adverse effects</term><term>Agranulocytosis</term><term>American academy</term><term>Antimalarial</term><term>Antimalarial therapy</term><term>Arch intern</term><term>Arthritis</term><term>Avascular</term><term>Avascular necrosis</term><term>Axis function</term><term>Axis suppression</term><term>Azathioprine</term><term>Baseline</term><term>Baseline value</term><term>Biopsy</term><term>Blood urea nitrogen</term><term>Bone abnormalities</term><term>Bone toxicity</term><term>Carcinoma</term><term>Cataract</term><term>Cessation</term><term>Clin</term><term>Clinical evaluation</term><term>Clinical presentation</term><term>Closure</term><term>Complication</term><term>Coronary artery disease</term><term>Corticosteroid</term><term>Corticosteroid dose</term><term>Corticosteroid therapy</term><term>Creatinine</term><term>Creatinine clearance</term><term>Critical toxicities</term><term>Cumulative dose</term><term>Cutaneous</term><term>Cutaneous conditions</term><term>Cyc1osporine</term><term>Cyclophosphamide</term><term>Cyclosporine</term><term>Daily dose</term><term>Dapsone</term><term>Dapsone therapy</term><term>Dermatol</term><term>Dermatologic</term><term>Dermatology</term><term>Determinant</term><term>Dos</term><term>Early symptoms</term><term>Engl</term><term>Epiphyseal</term><term>Epiphyseal closure</term><term>Etretinate</term><term>Etretinate therapy</term><term>Fasting</term><term>Function tests</term><term>Growth curve</term><term>Growth suppression</term><term>Guideline</term><term>Hepatocellular</term><term>Hepatocellular toxicity</term><term>Hepatotoxicity</term><term>High doses</term><term>High risk</term><term>Hyperlipidemia</term><term>Hypertension</term><term>Immunosuppressive</term><term>Immunosuppressive therapy</term><term>Inherent risk</term><term>Isotretinoin</term><term>Isotretinoin therapy</term><term>Ketoconazole</term><term>Laboratory tests</term><term>Lipid</term><term>Liver biopsy</term><term>Liver function tests</term><term>Major drugs</term><term>Malignancy</term><term>Malignancy induction</term><term>Malignancy risk</term><term>Methotrexate</term><term>Methotrexate therapy</term><term>Monitoring</term><term>Monitoring process</term><term>Ocular</term><term>Older patients</term><term>Organ transplantation</term><term>Osteoporosis</term><term>Particular emphasis</term><term>Patient characteristics</term><term>Photochemotherapy</term><term>Physical examination</term><term>Platelet</term><term>Platelet count</term><term>Pneumonitis</term><term>Premature epiphyseal closure</term><term>Proper monitoring</term><term>Psoriasis</term><term>Psoriasis patients</term><term>Puva</term><term>Puva therapy</term><term>Renal</term><term>Renal function</term><term>Renal function tests</term><term>Renal toxicity</term><term>Reticulocyte count</term><term>Retinoid</term><term>Retinoid therapy</term><term>Retinoids</term><term>Retinopathy</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Risk factors</term><term>Saunders</term><term>Side effects</term><term>Skin diseases</term><term>Specific toxicity</term><term>Syndrome</term><term>Systemic</term><term>Systemic drugs</term><term>Teratogenicity</term><term>Testing guidelines</term><term>Therapy</term><term>Toxicity</term><term>Transaminase</term><term>Transaminase values</term><term>Transplantation</term><term>Triglyceride</term><term>Uric acid</term><term>Urinalysis</term><term>Wilkin</term><term>Wolverton</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Systemic drugs with an associated element of risk are essential in managing many important dermatoses. This review identifies eight major drugs or drug groups used in dermatology that require systematic monitoring for adverse effects. The complete monitoring process is emphasized, including significant patient involvement in reporting key signs or symptoms that allow early diagnosis of many of these adverse effects. The concepts of “risk-risk” assessment and “critical toxicities” are defined, emphasizing their important role in maximizing drug benefits and safety. Drug-related risk factors, disease-specific risk factors, and patient characteristics or habits that increase the risks from systemic drugs are identified. Basic principles of monitoring for adverse effects, specific clinical features of the most important adverse effects, along with detailed monitoring guidelines for methotrexate, retinoids, dapsone, corticosteroids, and cyclosporine are presented.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Indiana</li></region></list><tree><country name="États-Unis"><region name="Indiana"><name sortKey="Wolverton, Stephen E" sort="Wolverton, Stephen E" uniqKey="Wolverton S" first="Stephen E." last="Wolverton">Stephen E. Wolverton</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E64 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002E64 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:EAAFCF9227565D97E8A3C04430934D14D9AEDC0D
|texte= Monitoring for adverse effects from systemic drugs used in dermatology
}}
| This area was generated with Dilib version V0.6.33. |  |